CN103239624A - Chinese medicine for treating oligospermia and asthenozoospermia owning to insufficiency of both spleen and kidney - Google Patents
Chinese medicine for treating oligospermia and asthenozoospermia owning to insufficiency of both spleen and kidney Download PDFInfo
- Publication number
- CN103239624A CN103239624A CN2013101700800A CN201310170080A CN103239624A CN 103239624 A CN103239624 A CN 103239624A CN 2013101700800 A CN2013101700800 A CN 2013101700800A CN 201310170080 A CN201310170080 A CN 201310170080A CN 103239624 A CN103239624 A CN 103239624A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- group
- radix
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines and in particular relates to a Chinese medicine for treating male infertility as well as a preparation method and an application thereof. The Chinese medicine composition is prepared from the following Chinese medicine raw materials in weight proportion: 30-600g of milkvetch, 10-300g of radix ophiopogonis, 10-300g of morinda officinalis, 5-120g of herba epimedii, 20-600g of prepared polygonum multiflorum, 30-600g of semen cuscutae and 20-500g of prepared sealwort. The Chinese medicine composition provided by the invention can be used for treating oligospermia and asthenozoospermia owning to insufficiency of both spleen and kidney.
Description
Technical field
The present invention relates to technical field of Chinese medicines, particularly relate to a kind of Chinese medicine composition for the treatment of male infertility and its preparation method and application.
Background technology
Male infertility is common clinically disease in the male sexual system, is subjected to influence of various factors such as environment.In infertile couples, male factor accounts for half ratio, is common type with few azoospermia again wherein.In recent years, about more and more being paid close attention to Chinese medicine preparation treatment male research few, azoospermia.The relative Western medicine of kidney-nourishing tcm drug that the traditional Chinese medical science is used is safer.
Summary of the invention
Purpose of the present invention aims to provide and a kind ofly treats less, the Chinese medicine composition of azoospermia and its preparation method and application.
Specifically, the invention provides a kind ofly treat less, the Chinese medicine composition of azoospermia, it is characterized in that it is to make with following Chinese medicine raw materials by weight proportion:
The Radix Astragali 30～600g, Radix Ophiopogonis 10～300g, Radix Morindae Officinalis 10～300g, Herba Epimedii 5～120g, Radix Polygoni Multiflori Preparata 20～600g, Semen Cuscutae 30～600g, Rhizoma Polygonati (processed) 20～500g.
In a preference, the weight proportion of described raw material of Chinese medicine is:
The Radix Astragali 60～240g, Radix Ophiopogonis 30～150g, Radix Morindae Officinalis 30～150g, Herba Epimedii 9～50g, Radix Polygoni Multiflori Preparata 50～300g, Semen Cuscutae 60～300g, Rhizoma Polygonati (processed) 50～200g.
In another preference, the weight proportion of described raw material of Chinese medicine is:
Radix Astragali 120g, Radix Ophiopogonis 60g, Radix Morindae Officinalis 60g, Herba Epimedii 20g, Radix Polygoni Multiflori Preparata 100g, Semen Cuscutae 160g, Rhizoma Polygonati (processed) 100g.
A second aspect of the present invention provided above-mentioned Chinese medicine composition preparation treatment less, application in the medicine of azoospermia.
A third aspect of the present invention has provided the preparation method of above-mentioned Chinese medicine composition, and it comprises the following steps: to get each crude drug mixes, decocting 2～3 times, and each 1～3 hour, add 4～20 times of amounts of water, decocting liquid is filtered merging namely.
The details of various aspects of the present invention will be able to detailed description in chapters and sections subsequently.By hereinafter and the description of claim, characteristics of the present invention, purpose and advantage will be more obvious.
Description of drawings
Fig. 1 matched group testis: the convoluted seminiferous tubule tube wall does not have and thickens, and the spermatogenic epithelium level does not have and increases or reduce, and as seen is in the spermatogenic cell (HEX100) of different developmental phases;
Fig. 2 matched group testis: the convoluted seminiferous tubule tube wall does not have and thickens, and the basement membrane heavy wall is normal, and the spermatogenic epithelium level does not have and increases or reduce, and as seen is in the spermatogenic cell (PASX100) of different developmental phases;
Fig. 3 matched group testis: the convoluted seminiferous tubule tube wall does not have and thickens, and the spermatogenic epithelium level does not have and increases or reduce, and as seen is in the spermatogenic cell (HEX100) of different developmental phases;
Fig. 4 matched group epididymis: the epididymal duct epithelial cell does not have degeneration, necrosis, sees the volume sperm in the tube chamber.Between matter do not have hyperemia, edema, no acute and chronic cell infiltration, Interstitial cell does not have hypertrophy (PASX100);
The positive group of Fig. 5 testis: the convoluted tubule of testis tube chamber does not have and subsides, visible spermatogenic cells at different levels, and a matter does not have hyperemia, edema, no acute and chronic cell infiltration, Interstitial cell does not have hypertrophy (HEX100);
The positive group of Fig. 6 testis: convoluted tubule of testis tube wall basement membrane does not have and thickens, and spermatogenic cell quantity is many, and a matter does not have hyperemia, edema, no acute and chronic cell infiltration, and Interstitial cell does not have hypertrophy (PASX100);
The positive group of Fig. 7 epididymis: the epididymal duct epithelial cell does not have degeneration, necrosis, sees the volume sperm in the tube chamber.Between matter do not have hyperemia, edema, no acute and chronic cell infiltration, Interstitial cell does not have hypertrophy (HEX100);
The positive group of Fig. 8 epididymis: the epididymal duct epithelial cell does not have degeneration, necrosis, sees the volume sperm in the tube chamber.Between matter do not have hyperemia, edema, no acute and chronic cell infiltration (PASX100);
Fig. 9 high dose group testis: convoluted tubule of testis tube wall level is thick, and the spermatogenic cell level is many, quantity is many, arrangement tight (black asterisk tubule), and volume mature sperm (green asterisk tubule) is arranged in the tube chamber.Between matter do not have hyperemia, edema, no acute and chronic cell infiltration, Interstitial cell does not have hypertrophy (HEX100);
Figure 10 high dose group testis: the convoluted seminiferous tubule thickness of pipe wall, the spermatogenic cell level is many, quantity is many, dense arrangement.The convoluted seminiferous tubule basement membrane does not thicken (PASX100);
Figure 11 high dose group epididymis: the epididymal duct epithelial cell does not have degeneration, necrosis, sees the volume sperm in the tube chamber.Between matter do not have hyperemia, edema, no acute and chronic cell infiltration, Interstitial cell does not have hypertrophy (HEX100);
Figure 12 high dose group epididymis: the epididymal duct intracavity is seen the volume sperm.Between matter do not have hyperemia, edema, no acute and chronic cell infiltration (PASX100);
Dosage group testis among Figure 13: the convoluted tubule of testis thickness of pipe wall, the spermatogenic cell level is many, quantity is many, arrangement tight (black asterisk tubule).Between matter do not have hyperemia, edema, no acute and chronic cell infiltration, Interstitial cell does not have hypertrophy (HEX100);
Dosage group testis among Figure 14: convoluted tubule of testis tube wall level is thick, and the spermatogenic cell level is many, quantity is many, arrangement is tight, and a matter does not have hyperemia, edema, no acute and chronic cell infiltration, and Interstitial cell does not have hypertrophy (PASX100);
Dosage group epididymis among Figure 15: the epididymal duct epithelial cell does not have degeneration, necrosis, sees the volume mature sperm in the tube chamber.Between matter do not have hyperemia, edema, no acute and chronic cell infiltration, Interstitial cell does not have hypertrophy (HEX100);
Dosage group epididymis among Figure 16: the epididymal duct epithelial cell does not have degeneration, necrosis, sees the volume mature sperm in the tube chamber.Between the matter NIP, Interstitial cell does not have hypertrophy (PASX100);
Figure 17 low dose group testis: convoluted tubule of testis tube wall level is thick, and the spermatogenic cell level is many, quantity is many, arrangement is tight, and a matter does not have hyperemia, edema, no acute and chronic cell infiltration, and Interstitial cell does not have hypertrophy (HEX100);
Figure 18 low dose group testis: convoluted tubule of testis tube wall level is thick, and the spermatogenic cell level is many, quantity is many, arrangement is tight, and a matter does not have hyperemia, edema, no acute and chronic cell infiltration, and Interstitial cell does not have hypertrophy (PASX100);
Figure 19 low dose group epididymis: the epididymal duct epithelial cell does not have degeneration, necrosis, sees the volume sperm in the tube chamber.Between matter do not have hyperemia, edema, no acute and chronic cell infiltration, Interstitial cell does not have hypertrophy (HEX100);
Figure 20 low dose group epididymis: the epididymal duct epithelial cell does not have degeneration, necrosis, sees the volume sperm in the tube chamber.Between matter do not have hyperemia, edema, no acute and chronic cell infiltration, Interstitial cell does not have hypertrophy (PASX100).
The specific embodiment
The present invention uses the Radix Astragali, Radix Morindae Officinalis, Herba Epimedii, QI invigorating kidney tonifying, supporing yang temperature fire.Wherein the Radix Astragali is solely heavy, benefiting qi and raising yang, warming middle-JIAO and strengthening the spleen; The Radix Morindae Officinalis settling five organs, beneficial marrow is mended fire and not bright water, and two medicines are monarch drug altogether.The hot temperature of Herba Epimedii plays male sexuality and declines, except pains in the penis; It is sweet flat to join Semen Cuscutae, the kidney invigorating and essence nourishing, and the usefulness of reinforcement monarch drug QI invigorating warming YANG is ministerial drug.Radix Polygoni Multiflori, Rhizoma Polygonati, nourishing the blood and yin, enriching kidney essence; Be slightly cold Radix Ophiopogonis, Yin-nourishing and body fluid promoting, and three medicines cooperate, and one helps the monarch and his subjects' YIN nourishing to mend essence, and the two anti-warm impairment of YIN blood that too consume of the monarch and his subjects are adjuvant drug.All medicines cooperate then temper foot, essence and blood to give birth to, and the elder generation's yang-energy day after tomorrow must be mended, cloudy smart must filling, and the equilibrium between yin and yang of kidney, marrow benefit foot amounts to warming and recuperating the spleen and kidney, the effect of YIN nourishing replenishing essence.
The Chinese crude drug Radix Astragali is the root of leguminous herbaceous plant's Radix Astagali, Radix Astragali, has effects such as invigorating QI to consolidate the body surface resistance, diuretic detumescent, expelling pus and toxin by strengthening QI, granulation promoting.Modern pharmacological research confirms: the Radix Astragali can strengthen the phagocytic function of reticuloendothelial system, and blood leukocytes and multinuclear leucocyte quantity are being shown to be increased, and macrophage phagocytic percentage rate and phagocytic index is being shown rise, and humoral immunization, cellular immunization are all had facilitation.In addition, the ability that the Radix Astragali can also the enhanced virus inducement interferon, promote organism metabolism, blood pressure lowering, protect the liver etc.
Be the tuber of liliaceous plant dwarf lilyturf Radix Ophiopogonis, cold nature, sweet in the mouth, little hardship.But nourishing YIN and moistening the lung, the relieving restlessness that clears away heart-fire, reinforcing stomach reg fluid.Modern pharmacological research confirms: reduce free radical Radix Ophiopogonis effectively, increase SOD, stabilizing cell membrane promotes the vascular endothelial cell energy metabolism, regulates the secretory function of vascular endothelial cell.Radix Ophiopogonis extract can significantly reduce the aggregation rate of rat platelet, reduces blood viscosity, thus prevention of stroke.Radix Ophiopogonis, n-butanol extract can obviously reduce the normal mouse blood sugar concentration, and dose dependent is arranged.Ophiopogonin and Radix Ophiopogonis polysaccharide can significantly increase mice organ thymus, spleen weight, and activate the phagocytic function of mice reticuloendothelial system, improve the serum hemolysin antibody horizontal, increase the immunity of body.
Radix Morindae Officinalis is the dry root of Maguireothamnus speciosus Radix Morindae Officinalis.Slightly warm in nature, acrid-sweet flavor has kidney-replenishing, bone and muscle strengthening, the cold function of dispeling the wind.Modern pharmacological research confirms: Radix Morindae Officinalis has various active such as the immunologic function of adjusting, adjusting thyroid function, defying age, resisting fatigue, hypermnesis, antitumor, promotion bone growth, promotion hemopoietic stem cell proliferation.
Herba Epimedii has another name called Herba Epimedii, is the dried leaves of Berberidaceae plant Herba Epimedii, arrow leaf Herba Epimedii, pubescence Herba Epimedii or Herba Epimedii.Acrid in the mouth, sweet, warm in nature.But kidney invigorating and YANG supporting; Expelling wind and removing dampness; Strong muscle key bone.Motherland's medical science thinks that Herba Epimedii has the effect of " beneficial vital essence, hard muscles and bones are mended the waist knee joint, heart tonifying power ".Modern medicine study confirms that also Herba Epimedii has the patrogenesis of adjusting, stops osteoporosis, regulates functions such as immunity, antioxidation, defying age, antitumor, anti-hepatotoxin, vasodilator.
Radix Polygoni Multiflori is the dried root of polygonum multiflorum thunb, its nature and flavor hardship, sweet, puckery, tepor.Pharmacology analysis shows that Radix Polygoni Multiflori contains anthraquinone analog compound, mainly contains chrysophanol and emodin, secondly is chrysophanic acid (product of processing do not contain chrysophanic acid), physcione and Radix Et Rhizoma Rhei anthrone, starch, crude fat, lecithin etc.The pharmacological action of Radix Polygoni Multiflori mainly contains: (1) slow down aging; (2) blood fat reducing and study of anti-atherogenic effect, Radix Polygoni Multiflori decoct can significantly reduce the content of plasma cholesterol, triglyceride and beta lipoprotein, and Radix Polygoni Multiflori energy blood fat reducing is described, delays atherosclerotic formation and development.(3) protect the liver, the tetrahydroxy ethylene-β in the Radix Polygoni Multiflori-D-glycoside is the effective ingredient that protects the liver, and it can prevent that fatty liver, liver function injury and liver lipid peroxide content from raising, and reduces serum glutamic pyruvic transminase and glutamic oxaloacetic transaminase, GOT; (4) antibiotic, the Radix Polygoni Multiflori is in the external growth that can suppress mycobacterium hominis, shigella flexneri, and its anthraquinone derivatives has in various degree inhibitory action to antibacterials such as staphylococcus aureus, streptococcus, diphtheria corynebacterium, anthrax bacillus and pathogen such as influenza virus, fungus.
Semen Cuscutae is the ripe dry seed of parasitics MANCAO cuscuta japonica Choisy.Nature and flavor are sweet, and are warm in nature.Can be by the kidney controlling nocturnal emission with astringent drugs, nourishing the liver to improve visual acuity, antidiarrheal, antiabortive.Modern pharmacological research confirms: Semen Cuscutae has tonifying YANG, increase hypothalamic-pituitary-ovarian short luteal function, heart tonifying, blood pressure lowering, delay effect such as cataract formation.
Rhizoma Polygonati is for being the dry rhizome of liliaceous plant Yunnan Rhizoma Polygonati, Rhizoma Polygonati or Polygonatum cyrtonema Hua.Nature and flavor are sweet, flat.But nourishing YIN and moistening the lung; Invigorating the spleen and replenishing QI, the nourishing kidney replenishing essence.Modern pharmacological research confirms: effects such as Rhizoma Polygonati has antibiotic, antiviral, resisting fatigue, antioxidation, slow down aging, stops blooding, resists myocardial ischemia, blood sugar lowering.
Chinese medicine composition of the present invention, it is to make with following Chinese medicine raw materials by weight proportion:
The Radix Astragali 30～600g, Radix Ophiopogonis 10～300g, Radix Morindae Officinalis 10～300g, Herba Epimedii 5～120g, Radix Polygoni Multiflori Preparata 20～600g, Semen Cuscutae 30～600g, Rhizoma Polygonati (processed) 20～500g.
The preferred weight proportioning of described raw material of Chinese medicine is:
The Radix Astragali 60～240g, Radix Ophiopogonis 30～150g, Radix Morindae Officinalis 30～150g, Herba Epimedii 9～50g, Radix Polygoni Multiflori Preparata 50～300g, Semen Cuscutae 60～300g, Rhizoma Polygonati (processed) 50～200g.
The most preferably weight proportion of described raw material of Chinese medicine is:
Radix Astragali 120g, Radix Ophiopogonis 60g, Radix Morindae Officinalis 60g, Herba Epimedii 20g, Radix Polygoni Multiflori Preparata 100g, Semen Cuscutae 160g, Rhizoma Polygonati (processed) 100g.
Chinese medicine composition of the present invention can use separately, perhaps adds appropriate amount of auxiliary materials by the conventional method of this area and makes various oral formulations such as granule, tablet, capsule, mixture, powder etc.
Chinese medicine composition of the present invention can prepare by the following method: get each crude drug and mix by said ratio, decocting 2～3 times, each 1～3 hour, add 4～20 times of amounts of water, decocting liquid is filtered merging, leave standstill, the leaching supernatant adds sucrose, be concentrated into about 1000ml, add an amount of sodium benzoate, filter, add water to about 1000ml, stir evenly, packing, both.Also can add appropriate amount of auxiliary materials again, further make other dosage forms according to a conventional method.For example, add dextrin, spray drying makes into fine powder, makes granule through dry granulation; Or add Sodium Hydroxymethyl Stalcs, micropowder silica gel, soluble starch, and lactose and magnesium stearate, mix homogeneously is with 95% ethanol granule processed; 80 ℃ of dry back tablet agents; Add an amount of micropowder silica gel, behind the mixing, incapsulate; Or the part fine powder adds citric acid, starch is made granule, and all the other fine powders add sodium bicarbonate, starch is made granule, after two kinds of granules add magnesium stearate, and mix homogeneously, tabletting.
Confirm that through following pharmacodynamics test Chinese medicine composition of the present invention has following beneficial effect:
(1) the yang deficiency symptom is improved significantly, can improve animal to low temperature stress tolerance;
(2) gonad there is good protective action, and can keeps the function of gonad to a certain extent;
(3) can significantly increase sperm count and sperm day growing amount, but can not cause the hypertrophy of the relevant organ of reproductive system and body of gland, to the effect that also has clear improvement of testosterone, rate of teratosperm and the motility of sperm of animal, illustrate that it has the Spermatogenic action of gentleness;
(4) can significantly promote the animal reproduction ability;
(5) immune system to animal has some improvement.
This shows; Chinese medicine composition of the present invention can improve the yang deficiency symptom of animal on the whole; improve the immunocompetence of animal; by its gentle Spermatogenic action; when significantly increasing animal sperm number and sperm day growing amount; can not cause the hypertrophy of animal genitals and body of gland, on the contrary gonad be had good protective action.It only is by the motor capacity that promotes sperm and the medicine that the film function is treated male infertility, so it has clinical expansion and using value that its wholistic therapy effect will obviously be better than existing those beyond doubt.
Chinese medicine composition of the present invention is to the experimentation of mice model of yang asthenia influence
1. experiment material
1.1 animal
Cleaning level ICR male mice, body weight 18-22 gram provides (laboratory animal production licence: SCXK(Soviet Union) 2007-0001 by Yangzhou University comparative medicine center; Laboratory animal occupancy permit: SYXK(Soviet Union) 2007-0030).
1.2 medicine:
Compound recipe XUANJU capsule, provide lot number by executing strong Pharmaceutical Group Co.,Ltd: 20100609. by Chinese medicine ingredients such as Formica fusca, Herba Epimedii, Fructus Lycii, Fructus Cnidiis.
Chinese medicine composition extractum of the present invention (25 times of concentrated solutions), Renji Hospital Attached to Medical College of Shanghai Jiaotong Univ. entrusts Shanghai first line of a couplet pharmaceutcal corporation, Ltd to produce Shanghai medicine word Z05060356 processed, lot number: 041226.The clinical people's using method of Chinese medicine composition of the present invention is oral, one time 25 milliliters, 2-3 time on the one.
1.3 medicine preparation, dosage and grouping
(1) positive drug: compound recipe XUANJU capsule, every dress 0.42g, 3 of people one time, 3 times on the one, people's one consumption per day is 3.78g/70kg people, being converted to mice is the 0.01g/20g body weight. mice administration volume 0.2ml/20g body weight, the medicinal liquid compound concentration is 0.01g/0.2ml=0.05g/ml, mice administration volume 0.2ml/20g body weight.
(2) the clinical people's using method of Chinese medicine composition of the present invention is oral, one time 25 milliliters, 2-3 time on the one.Clothes 50ml calculates by the day for human beings, and its mice dose,equivalent is the 0.13ml/20g body weight/day.
Chinese medicine composition extractum of the present invention (25 times of concentrated solutions) is got 2 milliliters of extractum, adds 48ml distilled water mixing and namely gets clinical human mixture.Four degree refrigerators are preserved.Approximately can reach and use in a week.
The heavy dose of group of Chinese medicine composition of the present invention: 2 times of dose,equivalents of mice administration are the 0.26ml/20g body weight/day.
Dosage group in the Chinese medicine composition of the present invention: mice administration dose,equivalent is the 0.13ml/20g body weight/day.
Chinese medicine composition small dose group of the present invention: 0.5 times of dose,equivalent of mice administration is the 0.065ml/20g body weight/day.
(3) hydrocortisone injection 20ml/ props up, and 100 milligrams every, concentration is 100mg/20ml=500mg/100ml=0.5g/100ml, is 0.5% hydrocortisone.Except the normal control group, all the other each treated animal every day gives 0.5% hydrocortisone according to the intramuscular injection of 12.5ml/Kg=0.125ml/10g body weight and makes the insufficiency of kidney-YANG model.
1.4 instrument and reagent:
The Sartorius electronic balance, German Sartorius company;
The mice swimming pool
The 1L beaker
Stopwatch
2. test method
2.1 experimental program:
Choose 60 of ICR male mices, body weight 18-22g is divided into 6 groups, 10 every group: the normal control group; The insufficiency of kidney-YANG model group; Compound recipe XUANJU capsule sun property of medicine matched group; Dosage group in the heavy dose of group of Chinese medicine composition of the present invention, the Chinese medicine composition of the present invention; Chinese medicine composition small dose group of the present invention.Except the normal group animal, give 0.5% hydrocortisone according to 12.5ml/Kg next day of every treated animal and make the insufficiency of kidney-YANG model.Behind the model group injection hydrocortisone, the same equal-volume distilled water that gives with normal group is irritated stomach.Give relative medicine respectively by group behind positive controls and each the administration treated animal injection hydrocortisone and irritate stomach, successive administration 30 days, after administration in the 30th day 1 hour, record each treated animal body weight, autonomic activities number and low temperature (four degree) swimming time-to-live in 10 minutes, the result carries out statistical procedures.
2.2 date processing: use Microsoft Excel software to carry out date processing to all data, and statistic analysis result.
3. result
3.1 Chinese medicine composition of the present invention is to the influence of mice insufficiency of kidney-YANG model autonomic activities and swimming time
By table 1 data as can be seen, the high, medium and low dosage group of Chinese medicine composition of the present invention all can significantly increase (p＜0.01) yang deficiency mice autonomic activities number of times (in the 10min); The high, medium and low dosage group of Chinese medicine composition of the present invention all can obviously prolong under (p＜0.01) mice cryogenic conditions swims the time-to-live, show that Chinese medicine composition of the present invention has tangible anti-yang deficiency effect, alleviate the yang deficiency degree, improve mice to low temperature stress tolerance.
Table 1 Chinese medicine composition of the present invention is to model of yang asthenia mice autonomic activities and the influence of low temperature swimming time-to-live
Compare * p＜0.05, * * p＜0.01 with normal group; Compare #p＜0.05, ##p＜0.01 with model group
4. conclusion
To the model of yang asthenia mice, all can alleviate the yang deficiency degree after each dose application of Chinese medicine composition of the present invention, have statistical significant difference.After the medication, the medicine of each dosage group all can significantly improve the autonomic activities number of times of mice, prolongs the low temperature swimming time.High dose group can make the low temperature swimming time-to-live near normal group.Show that Chinese medicine composition of the present invention improves significantly to the yang deficiency symptom of mice, can improve mice to low temperature stress tolerance.
Chinese medicine composition of the present invention is to the experimentation of rat castration insufficiency of kidney-YANG model influence
1. experiment material
1.1 animal: SD rat, 40-60 gram
90 of SD male rats, in age in 4-5 week, body weight 40～60g provides (laboratory animal production licence: SCXK(Zhejiang) 2008-0033 by Zhejiang Province's Experimental Animal Center; Laboratory animal occupancy permit: SYXK(Soviet Union) 2007-0030).
1.2 medicine:
Compound recipe XUANJU capsule, provide lot number by executing strong Pharmaceutical Group Co.,Ltd: 20100609. by Chinese medicine ingredients such as Formica fusca, Herba Epimedii, Fructus Lycii, Fructus Cnidiis.
Chinese medicine composition extractum of the present invention (25 times of concentrated solutions), Renji Hospital Attached to Medical College of Shanghai Jiaotong Univ. entrusts Shanghai first line of a couplet pharmaceutcal corporation, Ltd to produce Shanghai medicine word Z05060356 processed, lot number: 041226.The clinical people's using method of Chinese medicine composition of the present invention is oral, one time 25 milliliters, 2-3 time on the one.
1.3 medicine preparation, dosage and grouping
(1) positive drug: compound recipe XUANJU capsule, every dress 0.42g, 3 of people one time, 3 times on the one, people's one consumption per day is 3.78g/70kg people, being converted to rat is the 0.068g/200g body weight. rat administration volume 2ml/200g body weight, the medicinal liquid compound concentration is 0.068g/2ml=0.034g/ml, rat administration volume 2ml/200g body weight.
(2) the clinical people's using method of Chinese medicine composition of the present invention is oral, one time 25 milliliters, 2-3 time on the one.Clothes 50ml calculates by the day for human beings, and its rat dose,equivalent is the 0.9ml/200g body weight/day.
Chinese medicine composition extractum of the present invention (25 times of concentrated solutions) is got 2 milliliters of extractum, adds 48ml distilled water mixing and namely gets clinical human mixture.Four degree refrigerators are preserved.
The heavy dose of group of Chinese medicine composition of the present invention: 2 times of dose,equivalents of rat administration are the 1.8ml/200g body weight/day.
Dosage group in the Chinese medicine composition of the present invention: rat administration dose,equivalent is the 0.9ml/200g body weight/day.
Chinese medicine composition small dose group of the present invention: 0.5 times of dose,equivalent of rat administration is the 0.45ml/200g body weight/day.
1.4 instrument and reagent:
The Sartorius electronic balance, German Sartorius company;
BECKMAIV-COULTER DXI800 testosterone detectable lot number: 020111
FITC anti-rat CD3 antibody, PE anti-rat CD8 antibody, PE anti-rat CD4 antibody is provided by BIOLEGEND company.
BD FACSCalibur flow cytometer
2. test method
2.1 experimental program:
Laboratory animal is divided into 6 groups at random, and namely normal control group, model group, positive drug (compound recipe XUANJU capsule) are organized dosage group, Chinese medicine composition low dose group of the present invention in Chinese medicine composition high dose group of the present invention, the Chinese medicine composition of the present invention.12 every group of rats.The normal control group; Model group; Sun property of medicine matched group; Dosage group in the heavy dose of group of Chinese medicine composition of the present invention, the Chinese medicine composition of the present invention; Chinese medicine composition small dose group of the present invention.Except the normal group animal, all rat excision testis castrations are sewed up the incision.The random packet after second day of performing the operation is divided into model group and administration group.Model group and normal group give to irritate stomach with the volume distilled water, and the administration group gives the positive control medicine respectively and is subjected to the reagent thing according to group.Successive administration 30 days, once a day, 24 hours femoral artery sacrificed by exsanguination rats after last administration are collected rat blood and also carry out anticoagulant, divide to get 1ml and leave standstill centrifugal separation plasma after a period of time, and plasma sample detects the testosterone concentration in the blood plasma.The rat of putting to death is dissected, and cuts the internal organs such as prostate, seminal fluid capsule, levator ani of animal, weighs, and calculates organ index.
2.2 date processing: use Microsoft Excel software to carry out date processing to all data, and statistic analysis result.
3. result
3.1 Chinese medicine composition of the present invention is to the influence of rat castration insufficiency of kidney-YANG model organ coefficient
As can be seen from Table 2, compare with normal group, model group rat prostate and levator ani organ coefficient have significant difference (p＜0.01), show rat castration insufficiency of kidney-YANG model modeling success.With model group relatively, Chinese medicine composition of the present invention high, medium and low dosage group prostate and levator ani coefficient have significant difference (p＜0.01), show after the Chinese medicine composition administration of the present invention can significance to alleviate insufficiency of kidney-YANG degree after the rat castration.
Table 2 Chinese medicine composition of the present invention to the influence of rat castration insufficiency of kidney-YANG model organ coefficient (
N=10)
Annotate: compare * * p＜0.01 with normal group; Compare ##p＜0.01 with model group;
3.2. Chinese medicine composition of the present invention is to the influence of rat castration insufficiency of kidney-YANG model blood parameters:
As can be seen from Table 3, compare with normal group, testosterone levels obviously descends in the castrated rats body, Chinese medicine composition high dose of the present invention (p＜0.01) and middle dosage, low dose group (p＜0.05) all can improve testosterone levels in the castration male rat body by significance, and as seen medicine can be kept the testosterone levels in the rat body to a certain extent.
Table 3 Chinese medicine composition of the present invention to castration insufficiency of kidney-YANG rat model testosterone and immune influence (
N=10)
Annotate: compare * p＜0.05, * * p＜0.01 with model group.Compare #p＜0.05 with the blank group.
4. conclusion
To rat castration insufficiency of kidney-YANG model, all can alleviate the insufficiency of kidney-YANG degree after each dose application of Chinese medicine composition of the present invention, have statistical significant difference.Chinese medicine composition of the present invention can be kept the testosterone concentration in the rat body simultaneously.After the medication, the medicine of each dosage group all can significantly improve prostate coefficient and the levator ani coefficient of rat, shows that Chinese medicine composition of the present invention has good protective action to the gonad of male rat, and can keep the function of gonad to a certain extent.
Chinese medicine composition of the present invention is to the influence research of rat motility of sperm and form
1. experiment material
1.1 animal:
90 of SD male rats, in age in 4-5 week, body weight 40～60g provides (laboratory animal production licence: 2007-012 SCXK(army) by Nanking Military Area Command of the Chinese People's Liberation Army medical animal experiment center; Laboratory animal occupancy permit: SYXK(Soviet Union) 2007-0030).
1.2 medicine:
Compound recipe XUANJU capsule, provide lot number by executing strong Pharmaceutical Group Co.,Ltd: 20100609. by Chinese medicine ingredients such as Formica fusca, Herba Epimedii, Fructus Lycii, Fructus Cnidiis.
Chinese medicine composition extractum of the present invention (25 times of concentrated solutions), Renji Hospital Attached to Medical College of Shanghai Jiaotong Univ. entrusts Shanghai first line of a couplet pharmaceutcal corporation, Ltd to produce Shanghai medicine word Z05060356 processed, lot number: 041226.The clinical people's using method of Chinese medicine composition of the present invention is oral, one time 25 milliliters, 2-3 time on the one.
1.3 medicine preparation, dosage and grouping
(1) positive drug: compound recipe XUANJU capsule, every dress 0.42g, 3 of people one time, 3 times on the one, people's one consumption per day is 3.78g/70kg people, being converted to rat is the 0.068g/200g body weight. rat administration volume 2ml/200g body weight, the medicinal liquid compound concentration is 0.068g/2ml=0.034g/ml, rat administration volume 2ml/200g body weight.
(2) the clinical people's using method of Chinese medicine composition of the present invention is oral, one time 25 milliliters, 2-3 time on the one.Clothes 50ml calculates by the day for human beings, and its rat dose,equivalent is the 0.9ml/200g body weight/day.
Chinese medicine composition extractum of the present invention (25 times of concentrated solutions) is got 2 milliliters of extractum, adds 48ml distilled water mixing and namely gets clinical human mixture.Four degree refrigerators are preserved.
The heavy dose of group of Chinese medicine composition of the present invention: 2 times of dose,equivalents of rat administration are the 1.8ml/200g body weight/day.
Dosage group in the Chinese medicine composition of the present invention: rat administration dose,equivalent is the 0.9ml/200g body weight/day.
Chinese medicine composition small dose group of the present invention: 0.5 times of dose,equivalent of rat administration is the 0.45ml/200g body weight/day.
1.4 reagent
BECKMAIV-COULTER DXI800 testosterone reagent lot number: 020111
The glucose ringer solution, the laboratory autogamy
1.5 instrument:
The Sartorius electronic balance, German Sartorius company;
2. test method
2.1 experimental program:
Laboratory animal is divided into 5 groups at random, and namely normal control group, positive drug (compound recipe XUANJU capsule) are organized dosage group, Chinese medicine composition low dose group of the present invention in Chinese medicine composition high dose group of the present invention, the Chinese medicine composition of the present invention.10 every group of rats.Give rat oral gavage administration (1ml/100g) respectively by group, normal group then gives with volume distilled water (1ml/100g).Successive administration 35 days, once a day, 24 hours femoral artery sacrificed by exsanguination rats after last administration are collected rat blood and also carry out anticoagulant, divide to get 1ml and leave standstill centrifugal separation plasma after a period of time, and the plasma sample censorship detects the testosterone concentration in the blood plasma; The rat of putting to death is dissected, and cuts the internal organs such as prostate, seminal fluid capsule, levator ani of animal, weighs, and calculates organ index.Get a side epididymis and place the 20ml beaker, add 0.1% glucose ringer solution 2ml, suitably shred, jolting moves in the solution sperm at 30 degree insulation 10min automatically.Get 1 and put on the microscope slide, under low power microscope, observe the mobility of sperm, add up percentage rate and the head of sperm simultaneously respectively.The percentage rate of tail fracture sperm.And count sperm count at red, numeration of leukocyte plate.Opposite side epididymis and testis place formalin fixing, make tissue slice, and whether sperm receives damage and morphologic change in microscopy epididymal and the epididymis; Whether the microscopy testis tissue is normal.
2.2 date processing:
Use Microsoft Excel software to carry out date processing to all data, and statistic analysis result.
3. result
3.1 Chinese medicine composition of the present invention is to the influence of male rat organ coefficient
From each dosage group of the visible Chinese medicine composition of the present invention of table 4 data prostate, seminal vesicle fluid, testis, epididymis, the preputial glands of normal male rat do not had remarkable influence, can not cause the hypertrophy of these organs.
Table 4 Chinese medicine composition of the present invention to the influence of male rat organ coefficient (
N=10)
Compare * P＜0.05 with normal group; Compare #P＜0.01 with the positive drug group.
3.2. Chinese medicine composition of the present invention is to the influence of rat motility of sperm:
From each dosage group of the visible Chinese medicine composition of the present invention of table 5 data to can significantly improve normal male rat sperm count and sperm day growing amount, has the trend that improves testosterone levels in the male rat body, but compare no difference of science of statistics with normal group, but do not cause that rate of teratosperm improves.The prompting medicine has gentle Spermatogenic action and does not have the side effect that causes sperm deformity.
Table 5 Chinese medicine composition of the present invention to the influence of male rat testosterone and motility of sperm (
N=10)
Compare * * P＜0.01 with normal group; Compare ##P＜0.01 with the positive drug group.
4. conclusion
Chinese medicine composition of the present invention can significantly increase the male rat sperm count and sperm day growing amount, but can not cause the hypertrophy of the relevant organ of male rat reproductive system and body of gland, to the also obviously improvement effect of thing of testosterone, rate of teratosperm and motility of sperm of rat, the prompting medicine has gentle Spermatogenic action.
Chinese medicine composition of the present invention is to the histopathological study of rat testicle epididymis influence
1. material and method:
1.1. laboratory animal and grouping:
50 of rats, 5 groups, 10 every group.
Group: normal group, positive group (compound recipe XUANJU capsule), Chinese medicine composition high dose group of the present invention, dosage group in the Chinese medicine composition of the present invention, Chinese medicine composition low dose group of the present invention.
Pick up internal organs 1.2. send: testis and epididymis.
1.3. method: after testis and epididymis exsomatized, it was fixing to put into 10% formalin solution immediately, and routine is drawn materials, dehydration, paraffin embedding film-making, slice thick 4 μ m, and HE dyeing and PAS dye the morphological change of om observation testis and epididymis.Testis: the convoluted seminiferous tubule cell is arranged and to be had or not disorder, basement membrane to have or not to thicken, and the spermatogenesis phenomenon has no change (increase or reduce); Between matter have or not edema, Interstitial cell has or not hypertrophy.Epididymis: the epididymal duct epithelial cell has or not degeneration, necrosis, has or not sperm in the tube chamber, and a matter has or not hyperemia, edema, cell infiltration.According to the pathological changes light and heavy degree, sxemiquantitative is slight " ± " successively, slight "+", moderate " ++ ", severe " +++", no pathological changes tissue mark is "-".
2. result
2.1 normal group (10):
2.1.1. testis: the normal rat testis is made up of convoluted seminiferous tubule, the spermatogenic cell hierarchal arrangement of different developmental phases, from the basic unit of convoluted seminiferous tubule to tube chamber, be followed successively by spermatogonium, primary spermatocyte, secondary spermatocyte, spermatid, with chamber face The mature sperm, sustenticular cell is distributed between each phase spermatogenic cell.For being rich in blood vessel and vasculolymphatic loose connective tissue, wherein be also shown in a small amount of Interstitial cell between convoluted seminiferous tubule.(Fig. 1)
The basement membrane that dye in the peripheral Yihong of visible convoluted seminiferous tubule of PAS when dyeing, basement membrane do not have and thicken the spermatid no abnormality seen.(Fig. 2)
2.1.2. epididymis: the epididymal duct epithelial cell is column or cubic, no degeneration, necrosis, pathological changes such as come off, the visible volume mature sperm of intracavity.Between matter do not see vasodilation hyperemia, hemorrhage, cell infiltration.(Fig. 3)
The basement membrane that dye in the peripheral Yihong of visible epididymal duct of PAS when dyeing, basement membrane do not have and thicken sperm no abnormality seen in the tube chamber.(Fig. 4)
2.2. positive group (recurrence XUANJU capsule) (10):
2.2.1. testis: testis is no abnormal by the convoluted seminiferous tubule structure, the spermatogenic cell hierarchal arrangement of different developmental phases is orderly, from the basic unit of convoluted seminiferous tubule to tube chamber, be followed successively by spermatogonium, primary spermatocyte, secondary spermatocyte, spermatid, with chamber face The mature sperm, sustenticular cell is distributed between each phase spermatogenic cell.For being rich in blood vessel and vasculolymphatic loose connective tissue, wherein be also shown in a small amount of Interstitial cell between convoluted seminiferous tubule, the little edema of light weight between 2.(Fig. 5)
The basement membrane that dye in the peripheral Yihong of visible convoluted seminiferous tubule of PAS when dyeing, basement membrane do not have and thicken the spermatid no abnormality seen.(Fig. 6)
2.2.2. epididymis: the epididymal duct epithelial cell is column or cubic, no degeneration, necrosis, pathological changes such as come off, the visible volume mature sperm of intracavity.Between matter do not see vasodilation hyperemia, hemorrhage, cell infiltration.(Fig. 7)
The basement membrane that dye in the peripheral Yihong of visible epididymal duct of PAS when dyeing, basement membrane do not have and thicken sperm no abnormality seen in the tube chamber.(Fig. 8)
2.3 Chinese medicine composition high dose group of the present invention (10):
2.3.1. testis: testes histological structure is identical with normal group, and convoluted seminiferous tubule does not have obvious atrophy, subsides or expands, and each layer spermatogenic cell do not have obvious minimizing or increase, and a matter does not have obvious hyperemia, no cell infiltration, and matter has slight edema between 3.(Fig. 9)
The basement membrane that dye in the peripheral Yihong of visible convoluted seminiferous tubule of PAS when dyeing, basement membrane do not have and thicken, and spermatid quantity shows no obvious abnormalities.(Figure 10)
2.3.2. epididymis: the epididymal duct epithelial cell is column or cubic, no degeneration, necrosis, pathological changes such as come off, and the visible volume mature sperm of intracavity does not see that degeneration, non-viable non-apoptotic cell increase.Between the matter blood vessel do not have dilatation and congestion, hemorrhage, 7 no cell infiltration, matter has slight cell infiltration between 1, is mainly mononuclear phagocyte and lymphocyte.(Figure 11)
Basement membrane, the nothing that dye in the peripheral Yihong of epididymal duct during PAS dyeing thicken, and sperm shows no obvious abnormalities in the tube chamber.(Figure 12)
2.4. dosage group in the Chinese medicine composition of the present invention (10):
2.4.1. testis: testes histological structure is identical with normal group, and convoluted seminiferous tubule does not have obvious atrophy, subsides or expands, and each layer spermatogenic cell do not have obvious minimizing or increase, and a matter does not have obvious hyperemia, no cell infiltration, the little edema of light weight between 3.(Figure 13)
The basement membrane that dye in the peripheral Yihong of visible convoluted seminiferous tubule of PAS when dyeing, basement membrane do not have and thicken the spermatid no abnormality seen.(Figure 14)
2.4.2. epididymis: the epididymal duct epithelial cell is column or cubic, no degeneration, necrosis, pathological changes such as come off, and the visible volume mature sperm of intracavity is not seen volume degeneration, downright bad cell.Between the matter blood vessel do not have dilatation and congestion, hemorrhage, no cell infiltration.(Figure 15)
Basement membrane, the nothing that dye in the peripheral Yihong of epididymal duct during PAS dyeing thicken, and sperm shows no obvious abnormalities in the tube chamber.(Figure 16)
2.5 Chinese medicine composition low dose group of the present invention (10):
2.5.1. testis: testes histological structure is identical with normal group, and convoluted seminiferous tubule does not have obvious atrophy, subsides or expands, and each layer spermatogenic cell do not have obvious minimizing or increase, and a matter does not have hyperemia, edema and cell infiltration.(Figure 17)
The basement membrane that dye in the peripheral Yihong of visible convoluted seminiferous tubule of PAS when dyeing, basement membrane do not have and thicken the spermatid no abnormality seen.(Figure 18)
2.5.2. epididymis: the epididymal duct epithelial cell is column or cubic, no degeneration, necrosis, pathological changes such as come off, and the visible volume mature sperm of intracavity is not seen volume degeneration, downright bad cell.Between the matter blood vessel do not have dilatation and congestion, hemorrhage, no cell infiltration.(Figure 19)
Basement membrane, the nothing that dye in the peripheral Yihong of epididymal duct during PAS dyeing thicken, and sperm shows no obvious abnormalities in the tube chamber.(Figure 20)
3. conclusion
The high, medium and low dosage rat testicle of Chinese medicine composition of the present invention and epididymis convoluted seminiferous tubule in HE and PAS stained does not have obvious expansion or atrophy, and basement membrane does not have and thickens.Interstitial cell does not have hypertrophy or obviously reduces, and does not have significantly acute, chronic inflammatory reaction.
Chinese medicine composition of the present invention is to the experimentation of male mice reproductive function influence
1. experiment material
1.1 animal
Kunming mouse, 40 of bull mices, body weight 20-25 gram; 480 of adult female mices, body weight 20-25 gram.Provide (laboratory animal production licence: SCXK(Zhejiang) 2008-0033 by Zhejiang Province's Experimental Animal Center; Laboratory animal occupancy permit: SYXK(Soviet Union) 2007-0030).
1.2 medicine:
Compound recipe XUANJU capsule, provide lot number by executing strong Pharmaceutical Group Co.,Ltd: 20100609. by Chinese medicine ingredients such as Formica fusca, Herba Epimedii, Fructus Lycii, Fructus Cnidiis.
Chinese medicine composition extractum of the present invention (25 times of concentrated solutions), Renji Hospital Attached to Medical College of Shanghai Jiaotong Univ. entrusts Shanghai first line of a couplet pharmaceutcal corporation, Ltd to produce Shanghai medicine word Z05060356 processed, lot number: 041226.The clinical people's using method of Chinese medicine composition of the present invention is oral, one time 25 milliliters, 2-3 time on the one.
1.3 medicine preparation, dosage and grouping
(1) positive drug: compound recipe XUANJU capsule, every dress 0.42g, 3 of people one time, 3 times on the one, people's one consumption per day is 3.78g/70kg people, being converted to mice is the 0.01g/20g body weight. mice administration volume 0.2ml/20g body weight, the medicinal liquid compound concentration is 0.01g/0.2ml=0.05g/ml, mice administration volume 0.2ml/20g body weight.。
(2) the clinical people's using method of Chinese medicine composition of the present invention is oral, one time 25 milliliters, 2-3 time on the one.Clothes 50ml calculates by the day for human beings, and its mice dose,equivalent is the 0.13ml/20g body weight/day.
Chinese medicine composition extractum of the present invention (25 times of concentrated solutions) is got 2 milliliters of extractum, adds 48ml distilled water mixing and namely gets clinical human mixture.Four degree refrigerators are preserved.Approximately can reach and use in a week.
The heavy dose of group of Chinese medicine composition of the present invention: 2 times of dose,equivalents of mice administration are the 0.26ml/20g body weight/day.
Dosage group in the Chinese medicine composition of the present invention: mice administration dose,equivalent is the 0.13ml/20g body weight/day.
Chinese medicine composition small dose group of the present invention: 0.5 times of dose,equivalent of mice administration is the 0.065ml/20g body weight/day.
1.4 instrument and reagent:
The Sartorius electronic balance, German Sartorius company;
2. test method
2.1 experimental program:
Choose health, maturation, body weight the mice of 20-25g, 40 of male mices are divided into 5 groups at random, 8 every group; 400 of female mices are divided into 5 groups at random, 80 every group.Male mice gives distilled water, positive drug, the high, medium and low dosage of Chinese medicine composition of the present invention respectively by group.Successive administration 30 days, once a day, after administration the 23rd day, 1 of male mice is put among 10 female Mus groups with reproductive performance, and later every morning is used the normal saline flushing mouse vagina, and the person is the Mus of becoming pregnant to detect the sperm, examine 7 days altogether, record the Mus number of becoming pregnant, settle accounts average pregnancy rate, the difference between each group of statistics.
2.2 date processing:
Use Microsoft Excel software to carry out date processing to all data, and statistic analysis result.
3. result
3.1 Chinese medicine composition of the present invention is to the influence of male mice reproductive function
By table 6 data as can be seen, Chinese medicine composition object height of the present invention, middle dosage group all can significantly increase the fertilization success rate that the bull mice makes female mice, the average pregnancy rate of female mice significantly improves (p＜0.01), shows that Chinese medicine composition of the present invention has the effect of tangible enhancing male mice reproductive function.
Table 6 Chinese medicine composition of the present invention is to the influence of male mice reproductive function
Compare * p＜0.05, * * p＜0.01 with normal group;
4. conclusion
All can increase the pregnancy rate of female mice after Chinese medicine composition object height of the present invention, the middle dose application, have statistical significant difference.After the prompting medication, the male mice reproductive function of high, middle dosage group is significantly increased than the normal group male mice, and medicine can have the reproductive performance of remarkable lifting male mice.
The influence that the rat immunity function that Chinese medicine composition of the present invention causes cyclophosphamide suppresses
1. experiment material
1.1 animal:
90 of SD male rats, body weight 90-180g provides (laboratory animal production licence: SCXK(Zhejiang) 2008-0033 by Zhejiang Province's Experimental Animal Center; Laboratory animal occupancy permit: SYXK(Soviet Union) 2007-0030).
1.2 medicine:
Compound recipe XUANJU capsule, provide lot number by executing strong Pharmaceutical Group Co.,Ltd: 20100609. by Chinese medicine ingredients such as Formica fusca, Herba Epimedii, Fructus Lycii, Fructus Cnidiis.
Chinese medicine composition extractum of the present invention (25 times of concentrated solutions), Renji Hospital Attached to Medical College of Shanghai Jiaotong Univ. entrusts Shanghai first line of a couplet pharmaceutcal corporation, Ltd to produce Shanghai medicine word Z05060356 processed, lot number: 041226.The clinical people's using method of Chinese medicine composition of the present invention is oral, one time 25 milliliters, 2-3 time on the one.
1.3 medicine preparation, dosage and grouping
(1) positive drug: compound recipe XUANJU capsule, every dress 0.42g, 3 of people one time, 3 times on the one, people's one consumption per day is 3.78g/70kg people, being converted to rat is the 0.068g/200g body weight. rat administration volume 2ml/200g body weight, the medicinal liquid compound concentration is 0.068g/2ml=0.034g/ml, rat administration volume 2ml/200g body weight.
(2) the clinical people's using method of Chinese medicine composition of the present invention is oral, one time 25 milliliters, 2-3 time on the one.Clothes 50ml calculates by the day for human beings, and its rat dose,equivalent is the 0.9ml/200g body weight/day.
Chinese medicine composition extractum of the present invention (25 times of concentrated solutions) is got 2 milliliters of extractum, adds 48ml distilled water mixing and namely gets clinical human mixture.Four degree refrigerators are preserved.
The heavy dose of group of Chinese medicine composition of the present invention: 2 times of dose,equivalents of rat administration are the 1.8ml/200g body weight/day.
Dosage group in the Chinese medicine composition of the present invention: rat administration dose,equivalent is the 0.9ml/200g body weight/day.
Chinese medicine composition small dose group of the present invention: 0.5 times of dose,equivalent of rat administration is the 0.45ml/200g body weight/day.
1.4 instrument and reagent:
The Sartorius electronic balance, German Sartorius company;
FITC anti-rat CD3 antibody, PE anti-rat CD8 antibody, PE anti-rat CD4 antibody is provided by BIOLEGEND company.
BD FACSCalibur flow cytometer
2. test method
2.1 experimental program:
Laboratory animal is divided into 6 groups at random, and namely normal control group, model group, positive drug (compound recipe XUANJU capsule) are organized dosage group, Chinese medicine composition low dose group of the present invention in Chinese medicine composition high dose group of the present invention, the Chinese medicine composition of the present invention.10 every group of rats.Except the normal group animal, all rat single intraperitoneal injection cyclophosphamide random packet after 75mg/kg days is divided into model group and each administration group.Model group and normal group give to irritate stomach with the volume distilled water, and the administration group gives the positive control medicine respectively and is subjected to the reagent thing according to group.Successive administration 30 days, once a day, 24 hours femoral artery sacrificed by exsanguination rats after last administration are collected rat blood and carry out anticoagulant, and taking heparin anticoagulation 4ml places centrifugal 2000rpm on the lymphocyte separation medium, 20min.Draw the PBM at interface, Hanks liquid is washed once, centrifugal 1000rpm, 10min.Add dissolving people RBC liquid, 37 degree temperature are incubated 5min, the centrifugal 10min of 1000rpm.Hanks liquid is washed once, gets PBM1 * 106 cell/pipes, adds fluorescein-labeled CD respectively
3, CD
4, CD
8Monoclonal antibody or add different fluorescein-labeled antibody simultaneously and antibody diluent 100 μ l, 4 degree lucifuges down leave standstill 3min.Hanks liquid washed twice, the centrifugal 4min of 2000rpm, 30-40 μ m nylon membrane filter the back flow cytometer and detect.
2.2 date processing:
Use Microsoft Excel software to carry out date processing to all data, and statistic analysis result.
3. result
3.1 the influence that the rat immunity function that Chinese medicine composition of the present invention causes cyclophosphamide suppresses
As can be seen from Table 7, cyclophosphamide can obviously suppress the rat function, shows as rat CD3, CD4, and the cd8 cell level descends, the Chinese medicine composition high dose medicament of the present invention CD in the rat body that can significantly raise
3, CD4, the cd8 cell level is in the Chinese medicine composition of the present invention, low-dose drugs is for CD
3, CD
4, CD
8Expression all do not have the influence of significance, show that Chinese medicine composition of the present invention has certain improvement effect to the immune system of rat.
The influence that the rat immunity function that table 7 Chinese medicine composition of the present invention causes cyclophosphamide suppresses (
N=10)
Annotate: compare * p＜0.05, * * p＜0.01 with model group.Compare ##p＜0.01 with the blank group.
4. conclusion
The rat immunity function that the rat cyclophosphamide is caused suppresses model, and Chinese medicine composition high dose of the present invention can alleviate the downtrod degree of immunologic function after using, and has statistical significant difference.Show that Chinese medicine composition of the present invention has certain improvement effect to the immune system of rat.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used for explanation the present invention and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example is usually according to normal condition or the condition of advising according to manufacturer.Unless otherwise indicated, otherwise all percent, ratio, ratio or umber by weight.
Unless otherwise defined, the same meaning that employed all specialties and scientific words and one skilled in the art are familiar with in the literary composition.In addition, any method similar or impartial to described content and material all can be applicable in the inventive method.The usefulness that preferable implementation method described in the literary composition and material only present a demonstration.
The above-mentioned feature that the present invention mentions, or the feature that embodiment mentions can combination in any.All features that patent specification discloses can with any composition forms and usefulness, each feature that discloses in the description can anyly provide the alternative characteristics of identical, impartial or similar purpose to replace.Therefore except special instruction is arranged, the feature that discloses only is the general example of equalization or similar features.
Embodiment 1
Material Radix Astragali 30g, Radix Ophiopogonis 10g, Radix Morindae Officinalis 100g, Herba Epimedii 120g, Radix Polygoni Multiflori Preparata 600g, Semen Cuscutae 600g, Rhizoma Polygonati (processed) 500g get it filled.Decoct with water 2 times, add 12 times of amounts of water (weight ratio) for the first time and decocted 2 hours, add 6 times of amounts of water (weight ratio) for the second time and decocted 1.5 hours, decocting liquid filters, and merges, and is concentrated into relative density 1.35, adds an amount of lactose, makes granule 1000g, namely.
Embodiment 2
Radix Astragali 240g, Radix Ophiopogonis 150g, Radix Morindae Officinalis 30g, Herba Epimedii 50g, Radix Polygoni Multiflori Preparata 50g, Semen Cuscutae 60g, Rhizoma Polygonati (processed) 50g.Decoct with water 3 times, adding for the first time 10 times of amounts of water (weight ratio) decocted 1 hour, adding for the second time 8 times of amounts of water (weight ratio) decocted 1 hour, add 4 times of amounts of water (weight ratio) for the third time and decocted 0.5 hour, decocting liquid filters, and merges, the concentrating under reduced pressure drying, add appropriate amount of starch, lactose, magnesium stearate, make 1000 in tablet, namely.
Embodiment 3
Radix Astragali 600g, Radix Ophiopogonis, 30g, Radix Morindae Officinalis 10g, Herba Epimedii 9g, Radix Polygoni Multiflori Preparata 20g, Semen Cuscutae 30g, Rhizoma Polygonati (processed) 20g decocted with water 3 times, added 12 times of amounts of water (weight ratio) decoction 2 hours for the first time, add for the second time 10 times of amounts of water (weight ratio) and decocted 1 hour, decocting liquid filters, and merges, left standstill 6～8 hours, the leaching supernatant adds sucrose 85g, is concentrated into about 1000ml, add sodium benzoate 3g, filter, add water to 1000ml, stir evenly, packing, namely.
Embodiment 4
Radix Astragali 60g, Radix Ophiopogonis, 300g, Radix Morindae Officinalis 300g, Herba Epimedii 5g, Radix Polygoni Multiflori Preparata 300g, Semen Cuscutae 300g, Rhizoma Polygonati (processed) 200g decocted with water 2 times, added 8 times of amounts of water (weight ratio) decoction 1 hour for the first time, add for the second time 6 times of amounts of water (weight ratio) and decocted 1 hour, decocting liquid filters, and merges, left standstill leaching supernatant, concentrate drying 6～8 hours, pulverize, add appropriate amount of starch, lactose, mixing, encapsulated, make 1000, namely.
Embodiment 5
Radix Astragali 120g, Radix Ophiopogonis, 60g, Radix Morindae Officinalis 60g, Herba Epimedii 20g, Radix Polygoni Multiflori Preparata 100g, Semen Cuscutae 160g, Rhizoma Polygonati (processed) 100g decocted with water 2 times, added 12 times of amounts of water (weight ratio) decoction 2 hours for the first time, add for the second time 10 times of amounts of water (weight ratio) and decocted 1 hour, decocting liquid filters, and merges, left standstill 6～8 hours, the leaching supernatant adds sucrose 85g, is concentrated into about 1000ml, add sodium benzoate 3g, filter, add water to 1000ml, stir evenly, packing, namely.
Embodiment 6
Get the prepared oral liquid of embodiment 5, the treatment clinical diagnosis is patients with infertility 30 examples, and therapeutic scheme and result are as follows:
Administering mode: oral, one day 3 times, a 20ml.
The course for the treatment of: 24 weeks.
Curative effect determinate standard: compare with last semen analysis result before curative effect is judged to treat.
Cure: sperm concentration in the semen analysis 20 * 10
6ML
-1, and a+b level sperm ratio 50%, or a level sperm ratio 25%, or spouse's pregnancy during the treatment;
Produce effects: sperm concentration improves〉50%, and the more former radix of a+b level sperm ratio improves 50% or the more former radix of a level sperm ratio improve 50%;
Effectively: do not reach criterion of cure, sperm concentration improves〉25%, and the more former radix raising 25% of a+b level sperm ratio or the more former radix raising 25% of a level sperm ratio;
Invalid: do not reach criterion of cure, sperm concentration improves the more former radix raising＜25% of＜25%, a+b level sperm ratio or the more former radix of a level sperm ratio improves＜25%.
Therapeutic outcome: cure 10 examples, account for 33.33%; Produce effects 5 examples account for 16.67%; Effective 4 examples account for 13.33%; Invalid 11 examples account for 36.67%; Total effective rate is 63.33%.
Many aspects involved in the present invention have been done as above and have been set forth.Yet, it should be understood that before not departing from spirit of the present invention to put that those skilled in the art can be equal to change and modification to it, described change and modification fall into the coverage of the application's claims equally.
Claims (5)
1. treat that deficiency of spleen-YANG and kidneyYANG is few, the Chinese medicine composition of azoospermia for one kind, it is characterized in that it is to make with following Chinese medicine raw materials by weight proportion:
The Radix Astragali 30～600g, Radix Ophiopogonis 10～300g, Radix Morindae Officinalis 10～300g, Herba Epimedii 5～120g, Radix Polygoni Multiflori Preparata 20～600g, Semen Cuscutae 30～600g, Rhizoma Polygonati (processed) 20～500g.
2. Chinese medicine composition according to claim 1 is characterized in that, the weight proportion of described raw material of Chinese medicine is:
The Radix Astragali 60～240g, Radix Ophiopogonis 30～150g, Radix Morindae Officinalis 30～150g, Herba Epimedii 9～50g, Radix Polygoni Multiflori Preparata 50～300g, Semen Cuscutae 60～300g, Rhizoma Polygonati (processed) 50～200g.
3. Chinese medicine composition according to claim 1 and 2 is characterized in that, the weight proportion of described raw material of Chinese medicine is:
Radix Astragali 120g, Radix Ophiopogonis 60g, Radix Morindae Officinalis 60g, Herba Epimedii 20g, Radix Polygoni Multiflori Preparata 100g, Semen Cuscutae 160g, Rhizoma Polygonati (processed) 100g.
4. the application in the medicine of Chinese medicine composition as claimed in claim 1, azoospermia few at preparation treatment deficiency of spleen-YANG and kidneyYANG.
5. the preparation method of Chinese medicine composition as claimed in claim 1 is characterized in that, it comprises the following steps: to get each crude drug mixes, decocting twice, and each 1～2 hour, add 4～20 times of amounts of water, decocting liquid is filtered merging namely.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310170080.0A CN103239624B (en) | 2013-05-10 | 2013-05-10 | Chinese medicine for treating oligospermia and asthenozoospermia owning to insufficiency of both spleen and kidney |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310170080.0A CN103239624B (en) | 2013-05-10 | 2013-05-10 | Chinese medicine for treating oligospermia and asthenozoospermia owning to insufficiency of both spleen and kidney |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103239624A true CN103239624A (en) | 2013-08-14 |
| CN103239624B CN103239624B (en) | 2014-11-19 |
Family
ID=48919727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310170080.0A Expired - Fee Related CN103239624B (en) | 2013-05-10 | 2013-05-10 | Chinese medicine for treating oligospermia and asthenozoospermia owning to insufficiency of both spleen and kidney |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103239624B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379446A (en) * | 2018-03-30 | 2018-08-10 | 上海金城药业有限公司 | Co-enzyme Q 10 formulations and preparation method thereof with auxiliary treatment male's teen bra |
| CN108815379A (en) * | 2018-08-31 | 2018-11-16 | 王志强 | A kind of promotion raw ovum or the Chinese medicine of production of sperm and preparation method thereof |
| CN110538251A (en) * | 2019-09-25 | 2019-12-06 | 李明杰 | Traditional Chinese medicine composition for treating prostate diseases and preparation method and application thereof |
| CN112237607A (en) * | 2020-11-11 | 2021-01-19 | 武汉林宝莱生物科技有限公司 | Formula and preparation process of epimedium carbene tablet preparation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006930A (en) * | 2012-11-30 | 2013-04-03 | 重庆市中药研究院 | Application of ginseng and rhizoma curculiginis combined medicinal herbs in preparation of medicament for treating male infertility |
-
2013
- 2013-05-10 CN CN201310170080.0A patent/CN103239624B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006930A (en) * | 2012-11-30 | 2013-04-03 | 重庆市中药研究院 | Application of ginseng and rhizoma curculiginis combined medicinal herbs in preparation of medicament for treating male infertility |
Non-Patent Citations (1)
| Title |
|---|
| 王鸿祥等: "黄麦合剂治疗脾肾阳虚少和弱精症33例", 《医药导报》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379446A (en) * | 2018-03-30 | 2018-08-10 | 上海金城药业有限公司 | Co-enzyme Q 10 formulations and preparation method thereof with auxiliary treatment male's teen bra |
| CN108379446B (en) * | 2018-03-30 | 2021-05-04 | 上海金城素智药业有限公司 | Coenzyme Q10 preparation for adjuvant treatment of male oligospermia and preparation method thereof |
| CN108815379A (en) * | 2018-08-31 | 2018-11-16 | 王志强 | A kind of promotion raw ovum or the Chinese medicine of production of sperm and preparation method thereof |
| CN110538251A (en) * | 2019-09-25 | 2019-12-06 | 李明杰 | Traditional Chinese medicine composition for treating prostate diseases and preparation method and application thereof |
| CN112237607A (en) * | 2020-11-11 | 2021-01-19 | 武汉林宝莱生物科技有限公司 | Formula and preparation process of epimedium carbene tablet preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103239624B (en) | 2014-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100402081C (en) | Chinese patent medicine for treating gynaecologic disease and preparing method | |
| CN102106957A (en) | Chinese medicinal composition for treating hyperlipidemia | |
| CN103239624B (en) | Chinese medicine for treating oligospermia and asthenozoospermia owning to insufficiency of both spleen and kidney | |
| CN104984297A (en) | Application of pharmaceutical composition in preparation of drugs for treating amenorrhea | |
| CN103749818B (en) | A kind of sealwort hypoglycemic health protection tea and preparation method thereof | |
| CN104983916B (en) | There are health product of enhancing immunity and slow down aging and preparation method and application | |
| CN102813857A (en) | Chinese herbal Siyu blood-tonifying and kidney-nourishing preparation | |
| CN101095822B (en) | Chinese traditional medicine composition for treating leukemia and method of making the same | |
| CN106362104A (en) | Pharmaceutical composition for treating polycystic ovary syndrome in adolescence | |
| CN107188984B (en) | Polysaccharide composition and preparation method and application thereof | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN101703631B (en) | Chinese medicinal preparation for treating menopausal syndromes and impotence and preparation method thereof | |
| CN103585539B (en) | Traditional Chinese medicine composition for treating climacteric syndrome | |
| CN101816745B (en) | Chinese medicine composite applicable to treating ascitesduetocirrhosis and preparation method thereof | |
| CN111375022B (en) | Traditional Chinese medicine composition for treating prostatic hyperplasia | |
| CN103961506A (en) | Traditional Chinese medicine composition as traditional Chinese medicine regulatory human body cellular immunity agonist | |
| CN106420970A (en) | Pharmaceutical composition for curing premature ovarian failure | |
| CN1176794A (en) | Medicine for treating masculine sterility | |
| CN104840905A (en) | Traditional Chinese medicine capsule for treating non-small cell lung cancer | |
| CN104415162B (en) | Treat Chinese medicine composition of leukopenia after chemoradiotherapy and preparation method thereof | |
| CN106138715A (en) | A kind of defying age, the compound preparation and preparation method thereof of resisting fatigue | |
| CN107158143B (en) | Pharmaceutical composition for treating aplastic anemia and application thereof | |
| CN105709117A (en) | Traditional Chinese medicine composition containing argy wormwood leaves and used for female kidney-yang deficiency type ovulation failure | |
| CN104623415A (en) | Pharmaceutical composition for treating nephropathy and application thereof | |
| CN101461919B (en) | Medicament composition for treating male climacteric syndrome and delaying age |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141119 |